shown that a widely used antagonist of the human bradykinin B 2 receptor (B2R) HOE 14O acts as a full agonist of the chicken ornithokinin receptor (B oR). To understand the molecular mechanisms underlying differential efficacy of HOE 140 for the various kinin receptors, we have constructed chimeric kinin receptors (CKR) in which the amino-terminal portion including the first two transmembrane regions and the first extracellular loop (CKR-2) or only the second transmembrane region and the first extracellular loop (CKR-1) of B 2R were substituted with the corresponding segments of B oR. Ligand efficacy of synthetic ligand HOE 140 decreased in the order B oR Ͼ CKR-2 Ͼ CKR-1 Ͼ B 2R, whereas the efficacy of the endogenous kinin ligand was unchanged. Enhanced HOE 140 efficacy was not due to a structural change in the ligand binding site or to an enhanced receptor expression level. Rather, heterologous binding competition studies indicated that structural change(s) introduced into the engineered receptors caused a selective reduction in apparent affinity of HOE 140 for the uncoupled inactive receptor state R but not for the active G protein-coupled state R* , thereby increasing the ratio of R* over R for a given ligand concentration. Our results may help explain the unusually broad efficacy spectrum of HOE 140, which varies from inverse to full agonism, depending on kinin receptor subtype, tissue origin, or species. Birds have yet another subtype of kinin receptor, namely the ornithokinin receptor (B o R; also termed OKR), which couples to the G␣ q subtype (34). B o R is stimulated by the avian kinin homologue, i.e., [Thr 6 ,Leu 8
of kinin receptors, B 1 and B 2 , belonging to the large family of G protein-coupled receptors (32) . Typically, kinin receptors couple to G proteins of the G␣ q subtype, which trigger phospholipase C-mediated pathways signaling through inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ] and Ca 2ϩ (29, 30) before they are silenced by sequestration and phosphorylation (8, 21) . ]bradykinin. In contrast, the B 2 receptors (B 2 R) are activated by the full-length peptides bradykinin and Lys-bradykinin (kallidin) and inhibited by kinin analogs having a D-aromatic residue in position 7, as exemplified by HOE 140 (4) . Birds have yet another subtype of kinin receptor, namely the ornithokinin receptor (B o R; also termed OKR), which couples to the G␣ q subtype (34) . B o R is stimulated by the avian kinin homologue, i.e., [Thr 6 ,Leu 8 ]bradykinin ("ornithokinin") but is unresponsive to bradykinin or [des-Arg 9 ]bradykinin. Unexpectedly, HOE 140, a widely used B 2 R antagonist, was found to be a full agonist for B o R (34) . Depending on the species origin of the kinin receptors, HOE 140 has been characterized as an inverse agonist (23, 28) , neutral antagonist (14, 37) , partial agonist (10, 11, 17) , or full agonist (8, 34) . Furthermore, HOE 140 was reported to act as an inverse agonist or partial agonist on constitutively active kinin receptors (10, 37) . Thus a single ligand HOE 140 appears to display a spectrum of activities ranging from inverse and partial to full agonism, depending on the cell system expressing the kinin receptor. At present, the molecular mechanisms causing differential efficacy of HOE 140 for the various kinin receptor (sub)-types are still being debated.
Drug efficacy denotes the capacity of a ligand L to activate or to inactivate a receptor response (19, 24, 36) . The allosteric ternary complex model for G protein-coupled receptors (33) explains differences in ligand efficacy by the spontaneous isomerization of a given receptor between a basal, inactive conformational state (R) and an active conformational state (R*) that associates with a G protein to form R* G, which triggers an intracellular response (18) . Any perturbation in the equilibrium between R and R* will modulate receptor activity (25) . In this model, ligand efficacy critically depends on the capacity of the ligand to stabilize R* within the ternary complex of L ⅐ R* ⅐ G thereby shifting the equilibrium between R and R* toward the active, G protein-coupled receptor conformation (6, 25, 33) .
Here we have addressed the molecular mechanisms underlying differential efficacy of the peptidic ligand HOE 140 for kinin receptors. Using wild-type and chimeric kinin receptors expressed in Chinese hamster ovary (CHO) or COS-7 cells, we demonstrate that the structural variability in the amino-terminal domains translates into differential ligand affinity for the corresponding inactive receptor conformers and thus into grossly varying ligand efficacy for the different kinin receptor types.
EXPERIMENTAL PROCEDURES
Construction of chimeric receptors. The cDNAs of avian B oR and human B2R (B2R) were cloned into the EcoRI site of pBluescript (pBS, from Stratagene). A single HpaI restriction site was introduced into both receptor cDNAs using the QuickChange Site-directed Mutagenesis Kit (Stratagene) with the following primers: B oR-HpaI-CT 5Ј-CTATGTAAAGCTGT-TAACACAATCAA-CTAC-3Ј; BoR-HpaI-NT 5Ј-GTAGTTGATT-GTGTTAACAGCTTTACATAG-3Ј; B2R-HpaI-CT 5Ј-CTCTG-CCGCGTGGTTAACGCCATTATCTCC-3Ј; and B2R-HpaI-NT 5Ј-GGAGATAATGGCGTTAACCACGCGGCCAGAG-3Ј.
The position of the HpaI site corresponds to the extreme carboxy-terminal segment of extracellular domain (ED2) of B oR and B2R.
To construct chimeric kinin receptor (CRK)-1, we engineered an AvrII site into the cDNAs of CKR-2 (see below) and B 2R using the following primers: CKR-AvrII-CT: 5Ј-GCTGAAATT-TACCTAGGAAACATGGCTTTG-3Ј; CKR-AvrII-NT: 5Ј-CAA-ATGCCATGTTTCCTAGGTAAATTTCAGC-3Ј; B 2R-AvrII-CT: 5Ј-GCAGAGATCTACCTAGGGAACCTGGCCGC-3Ј; B2R-AvrII-NT: 5Ј-GCGGCCAGGTT-CCCTAGGTAGATCTCTGC-3Ј.
The position of the newly generated AvrII sites corresponds to the extreme carboxy-terminal segment of the intracellular domain (ID1) of CKR and B 2R. Transfer of the 5Ј end of the B2R cDNA corresponding to ED1, transmemebrane (TM)1, and ID1 generated the CKR-1 (Fig. 1) .
For the construction of CKR-2 the newly generated HpaI sites of the receptor cDNAs and the BamHI site of pBS were used; in this way the 5Ј region of B oR encoding the aminoterminal portion including ED2 was fused to the 3Ј segment of the B 2R cDNA encoding the carboxy-terminal portion of the receptor from transmembrane domain-3 (TM3) onward (Fig. 1) . The cDNAs for CKR receptors were excised from pBS and ligated into a pED4 expression vector (kindly provided by Dr. Kaufmann) using BglII and SmaI restriction sites. The integrity of chimeric cDNA constructs was verified by DNA sequence analysis.
Cell culture. The pED4 vectors harboring the relevant cDNAs were transfected into dihydrofolate reductase-deficient (DHFR Ϫ ) CHO cells using lipofectamine (Life Technologies). After 24 h, the transfected cells were split 1:10 into medium containing 250 nM methotrexate. Two weeks later transfectants were isolated by single cell cloning. Receptor expression was probed by specific binding using [3-(4-hydroxyphenyl-propyl) 125 I]HOE 140 (kindly provided by Hoechst, Frankfurt, Germany) or [2,3-prolyl-2,4-3 H(N)]bradykinin (DuPont); alternatively ligand-promoted total inositol phosphate (InsP n) accumulation was measured to monitor receptor expression. COS-7 cells were grown in DMEM supplemented with 10% fetal calf serum and transfected using the diethylaminoethyl-dextran method (34) .
Determination of inositol phosphates. Inosital phosphate hydrolysis was determined by the original method (2) as subsequently modified (15) . Clonal CHO cells were grown to confluence in 24-well plates and labeled with myo [2- 3 H]-inositol (1 Ci/ml) for 12 h in serum-free medium. After incubation with 10 mM LiCl for 15 min, the cells were stimulated for 10 min at 37°C with various ligands at the indicated concentrations. The released inositol phosphates were purified by anion exchange chromatography (Dowex 1ϫ8) and quantified by liquid scintillation counting. CHO clones were stimulated with aluminum tetrafluoride AlF 4 Ϫ as described (31) .
Ligand binding studies. Radioligand binding assays were done as described (26) Bound ligand was separated from free ligand by filtration through a Whatman GF/C filter followed by three washes with PBS, and the activity of the samples was determined by scintillation counting. For binding studies in the presence of guanylyl-5Ј-imidodiphosphate [Gpp(NH)p], cell membranes were prepared in 10 mM KH 2PO4, pH 6.8, 1 mM EDTA, 100 M phenylmethanesulfonyl fluoride, 1 M leupeptin, and 0.014 mg/ml bacitracin (22) . Freshly prepared membranes were incubated with 10 M Gpp(NH)p for 15 min, and the binding assays were performed as above. Data were analyzed by the Origin 4.0 program (MicroCal). IC 50 values reflecting apparent affinities are presented as means Ϯ SD for five independent experiments, each performed in triplicate. The efficacy of HOE 140 (1 M) was calculated as a fraction of the maximum response by the cognate ligand (set to 100%), i.e., 1 M bradykinin for B 2R, CKR-2, and CKR-1, and 1 M ornithokinin for BoR. Receptor density was calculated from Scatchard transformation of saturation binding analysis data using Origin 4.1. To measure bradykinin-induced contraction of guinea pig ileum, sections of the terminal ileum (2 cm long) were dissected, washed free of fecal contents, hung in Tyrode solution, and bubbled with 98% O 2-2% CO2 (5). After 1 h of relaxation, with frequent changes of buffer, a dose-response curve to bradykinin was determined, allowing 5 min between challenges. New compounds to be tested were added to the bath, followed by an ED 50 dose of bradykinin 30 s later. If the tissue contracted following the addition of the new compound alone, agonist potency was determined relative to the ED 50 of bradykinin. If the compound was an antagonist, its potency was measured as the pA2 value, defined as the negative logarithm of the dose of antagonist that reduces the effect of a 2ϫ dose agonist to that of an x dose in the absence of antagonist (1) .
Peptide synthesis. Peptides were synthesized by the standard BOC-benzyl solid phase synthesis (35) , purified and characterized by high performance liquid chromatography, amino acid analysis, and laser desorption mass spectrometry (Table 1) .
RESULTS

B 2 R antagonists act as B o R agonists.
HOE 140, the "classic" antagonist of mammalian kinin B 2 receptors, is a potent agonist of the chick ornithokinin receptor (34) . Initially, we sought to determine whether this effect is specific for HOE 140, or whether the phenomenon holds for other established B 2 R antagonists. To this end we selected five prototypic B 2 R antagonists (Table 1) Chimeric receptors show enhanced efficacy of HOE 140. Because differential ligand efficacy may reflect the structural context of the various receptors, we created chimeric receptors by combining complementary domains of human B 2 R and chick B o R. CKR-1 consisted of the amino-and carboxy-terminal portions of B 2 R and a short segment of B o R, including TM2 and ED2 (Fig.  1) . B 2 R and CKR-1 were recombinantly expressed in COS-7 cells, and dose-response curves of InsP n accumulation were analyzed after stimulation with 1 M bradykinin or HOE 140. Bradykinin showed similar EC 50 values (Fig. 3A) and almost identical efficacies (data not shown) for B 2 R and CKR-1. Also the maximal B2R, human bradykinin B2 receptor; B0R, ornithokinin receptor; CKR-1 and -2, chimeric kinin receptor 1 and 2, respectively. The chemical structure of substituting artificial amino acids is as follows: Cpg; ␣-cyclopentanylglycine; Hyp, trans-4-hydroxyproline; Igl, ␣-2-indanylglycine; NChg, N-cyclohexylglycine; Oic, octahydroindole-2-carboxylic acid; Thi, ␤-2-thienylalanine; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. With the exception of S911486, the free acid form of the peptide was used. Determination of pA2 and EC50 values is specified in EXPERIMENTAL PROCEDURES.
effect (E max ) were almost identical for both kinin receptors (Table 3) suggesting that similar copy numbers of functional B 2 R and CKR-1 receptors are expressed on the cell surface. By contrast HOE 140 showed a 2.3-fold decrease in EC 50 values (Fig. 3B) , a 1.9-fold increase in efficacy (Table 2) , and a 1.8-fold increase in the E max values (Table 3) (Table 2) . We also constructed chimeric receptor CKR-2 with an extended amino-terminal portion of B o R fused to the B 2 R sequence at the junction of ED2 and TM3 (Fig. 1 ) and expressed it in COS-7 cells. Dose-response curves demonstrated that EC 50 (Fig. 3A) , efficacy (data not shown), and E max values (Table 3 ) of bradykinin were similar for CKR-2 and wild-type B 2 R. Thus efficacy, potency, and E max for bradykinin were almost uniform at CKR-1, CKR-2, and B 2 R. For HOE 140 and CKR-2, EC 50 values dropped 17-fold, efficacy increased 3.1-fold, and E max values increased 3-fold compared with wild-type B 2 R matching the corresponding parameters for HOE 140 and wild-type B o R ( Fig. 3B ; Tables 2 and  3) . Hence, replacement of the entire amino-terminal portion of B 2 R (amino acid positions 1-127) by the corresponding segments of B o R "transfers" full agonistic activity of HOE 140 from chicken B o R to human B 2 R without apparent loss of potency of the authentic B 2 R ligand bradykinin.
Increased HOE 140 efficacy does not reflect increased receptor density. We asked whether different expression levels are responsible for the change in efficacy of HOE 140 and whether the increased efficacy of HOE 140 at CKR receptors also holds for cells other than COS-7. Studying three distinct CHO clones expressing varying copy numbers of B 2 receptors, we found that the variation of E max for bradykinin (7-to 18-fold InsP n accumulation) was not correlated to receptor density (Fig. 4) . For instance, clone 2 had a 2.1-fold higher receptor density than clone 3, yet the latter clone had a 1.8-fold higher E max than the former (Fig. 4, left) . By contrast E max correlated well with InsP n accumulation induced by the nonspecific G protein activator aluminum tetrafluoride (AlF 4 Ϫ ), suggesting that the observed clonal variability in E max may well be due to different levels and activities of G q and/or phospholipase C. We obtained similar results when we studied clones 4 and 5 overexpressing CKR-1, i.e., E max was not correlated with receptor density, whereas it paralleled ligandindependent AlF 4 Ϫ -induced InsP n accumulation (Fig. 4,  right) . Thus ligand efficacy of HOE 140 is not correlated with receptor density. These results also demonstrate that increased HOE 140 efficacy at CKR-1 is not a COS cell-specific phenomenon.
Increased HOE 140 efficacy is not due to change in ligand binding site. The observation that HOE 140 efficacy at chimeric receptors is markedly increased prompted us to ask whether this effect reflects structural changes in the corresponding ligand binding sites and/or introduction of a new HOE 140 binding site into the chimeras. To address the first question, we measured the agonistic potencies of five selected HOE 140 derivatives for CKR-1 and CKR-2 and compared them with their antagonistic potencies in the B 2 R system ( Fig. 2 and Table 1 ). A linear correlation was found, consistent with the classic pharmacological criteria for identical HOE 140 binding sites at the various receptors (r ϭ 0.98 Ϯ 0.003 and 0.99 Ϯ 0.001 for CKR-1 and CKR-2, respectively). We also determined the rank orders of the potency of the various ligands with the wild-type receptors B 2 R and B o R, as well as for the chimeric receptors CKR-1 and CKR-2: they were invariably HOE 140 Ͼ B10038 Ն S911486 Ͼ B8852 Ͼ S900765 ( Table 1 ), suggesting that the binding sites were essentially identical for the various kinin receptors. Thus increased HOE 140 efficacy is not simply due to an altered ligand binding site.
Efficacy correlates inversely with apparent ligand affinity for uncoupled receptor state. Given that the ligand binding sites among the various kinin receptor types are largely identical, we asked whether Results are means Ϯ SD of three independent experiments, performed in duplicate. ND, not determined. To measure ligand potency for the various receptors, the total inositol trisphosphate (InsP3) accumulation assay was employed in Chinese hamster ovary (CHO) and COS-7 cells expressing recombinant kinin receptors. EC50 values were calculated from dose-response curves using 100 pM to 10 M of the ligand. Efficacy of 1 M HOE 140 was calculated as a fraction of the maximum response (set 100%) evoked by the natural ligand, i.e., 100 nM bradykinin for B2R, CKR-2, and CKR-1, and 100 nM ornithokinin for B0R. B2R clone-3 and CKR-1 clone-2 were used. (Fig. 5, A and C) . Uncoupling of the receptors from their G proteins in the presence of 10 M Gpp(NH)p drastically changed this uniform picture, whereas the apparent IC 50 of bradykinin for B 2 R, CKR-1, and CKR-2 did not significantly change under these conditions (Fig. 5D) , the apparent IC 50 for HOE 140 decreased as much as 500-fold to 35.0 Ϯ 6.0 nM (B 2 R), 78.5 Ϯ 7.2 nM (CKR-1), 611 Ϯ 63 nM (CKR-2), and 692 Ϯ 78 nM (B o R) (Fig. 5B) . For HOE 140, the rank order of apparent IC 50 for the uncoupled receptors, i.e., B 2 R Ͼ CKR-1 ϾϾ CKR-2 Ϸ B o R, exactly mirrored the order of efficacy, i.e., B o R Ϸ CKR-2 Ͼ CKR-1 Ͼ B 2 R, indicating an inverse relationship between efficacy and apparent affinity of HOE 140 for the uncoupled receptor state.
Change in receptor conformation modulates ligand efficacy. Differential ligand affinity for uncoupled receptors may reflect differences in the conformations of the various receptors. To address this hypothesis we applied heterologous competition binding assays using [ which translate into different ligand affinities for the inactive, but not for the active receptor states.
DISCUSSION
The fundamental nature of the molecular mechanisms by which agonist binding to G protein-coupled receptors promotes biological activity is a central issue in molecular pharmacology (33) . The ternary complex model for G protein-coupled receptors predicts that the agonistic activity of a given ligand is governed by the ratio of ligand affinities for the G protein-coupled, active receptor state R* and for the uncoupled, inactive receptor state R, respectively (19) . Thus neutral antagonists, partial agonists, and full agonists are thought to differ by progressively increasing their binding affinity for R* . The major accomplishment of the work presented herein is the experimental demonstration that the same effect, i.e., an increase in efficacy, can be achieved by selectively changing the structure of kinin receptors, thereby reducing the ligand affinity for the uncoupled state R while maintaining the high ligand affinity for R* , and thus shifting the equilibrium toward the coupled, active receptor state. We have exemplified this effect for wild-type and CKR and their major synthetic ligand HOE 140 and conclude that the ratio of the active complex L ⅐ R* ⅐ G and the inactive complex L ⅐ R increases among the various kinin receptor types because the apparent affinity of HOE 140 for the corresponding R states decreases by a factor of Ͼ500, whereas the apparent affinity for R* remains constant. The net effect of this equilibrium shift is an increased efficacy of HOE 140 in the order B o R Ͼ CKR-2 Ͼ CKR-1 Ͼ B 2 R.
The progressively lowered affinity of HOE 140 for the uncoupled receptor state, i.e., B 2 R Ͼ CKR-1 Ͼ CKR-2 Ͼ B o R, is not simply due to structural differences in the corresponding ligand binding sites because both HOE 140 and bradykinin show high affinity binding for their corresponding receptors in homologous competition assays. Furthermore, the linear correlation between agonist potency for B o R and antagonist potency for B 2 R of a panel of structurally divergent ligands lends further credit to the notion that the various ligands recognize similar, if not identical, binding sites on the various kinin receptors. Alternatively, each receptor might exist in two distinct conformers, one binding bradykinin and the other HOE 140 and its derivatives. Indeed, mutagenesis studies have revealed that HOE 140 and bradykinin exhibit overlapping though distinct binding sites on B 2 R, and that mutated kinin receptors may selectively bind HOE 140 but not bradykinin (16) . The most striking effect was found for the mutation F261A in TM6, which lowered the affinity for bradykinin by a factor of Ͼ2,000 but left the affinity of HOE 140 almost unchanged (16) . We took advantage of this finding and extended it to B o R: mutation of the conserved phenylalanine residue (F261A) in B o R drastically reduced the apparent affinity of the authentic ligand ornithokinin, but had little, if any, effect on HOE 140 binding (C. Schroeder, unpublished experiments). These findings reemphasize the idea 1) that B 2 R and B o R expose similar HOE 140 binding sites, and 2) that the two receptors have overlapping but not identical binding sites for the various bradykinin-like ligands.
The observed reduction in apparent affinity in heterologous competition binding studies for B o R and CKR could be explained by a decreased allosteric transformation rate among receptor conformers, which reduces the apparent affinity of the competing ligand. Isomerization between different receptor conformers has been suggested for the neurokinin NK 1 receptor where the demonstration of two distinct NK 1 receptor conformers blunted an unsuccessful quest for new NK 1 subtypes (27) . Mutations affecting allosteric transitions between receptor conformers without concomitant change in ligand affinity have also been reported for the thrombin receptor (13) and for the nicotinic acetylcholine receptor (12) . At present we can only speculate that similar conformational changes slowing allosteric transitions of kinin receptors may directly or indirectly reduce the apparent affinity of HOE 140 for the uncoupled receptor state. For instance, the slow interconversion rate among receptor conformers may have allowed us to "capture" a reduced affinity in the pseudosteady state of our radioligand binding assay.
With the advent of constitutively active receptors (33) and overexpression systems for wild-type receptors (6, 20) , it became apparent that ligands preferentially binding to the basal receptor state may reduce the spontaneous receptor activity and therefore act as inverse agonists. Indeed HOE 140 has been shown to be an inverse agonist at rat myometrial B 2 R (23) or at human B 2 R in COS-7 cells (28) . Furthermore, HOE 140 is a partial agonist for B 2 R from species such as trout (17) , sheep (11) , guinea pig (9), and humans (10) . Finally, conversion from the inverse to partial agonism or vice versa (7) has been reported for HOE 140 with human B 2 R and constitutively active mutants thereof (10, 28) . One possible explanation for these seemingly discrepant findings is that the specific action of HOE 140 and related compounds may be regulated by the levels of spontaneous activity and basal desensitization of B 2 R, which vary with cellular context (22, 28) . Because such a possibility is in direct conflict with the two-state receptor model, a three-state model has been proposed that hypothesizes an intermediate, partially active B 2 R conformer that is not fully functionally coupled to the G protein (28) .
A more straightforward interpretation holds that the ratio of binding affinities of HOE 140 toward the R and R* state(s) dictates the efficacy of the ligand, and that apparent binding affinity may vary among the conformers of various kinin receptor subtypes. At one extreme a very low binding affinity of HOE 140 for R drives almost all of the receptors toward the active LR* G state, and thus HOE is a full agonist. At the other extreme a very high binding affinity of HOE 140 for R shifts the equilibrium between R and R* further toward R thus making HOE 140 an inverse agonist. In this scenario the efficacy or "intrinsic" activity is not an endogenous feature of a given ligand; rather it depends on receptor subtype and/or cellular context, and therefore may vary widely. Thus our findings may help explain species-and tissue-specific differences in the efficacy of HOE 140 and reconcile apparently conflicting results published for HOE 140 and related compounds such as NPC17731 (23, 28) . Clearly, the pharmacological classification of a prototypical kinin receptor ligand such as HOE 140 is only valid in a given cellular setting.
